IRVINE, Calif., June 4, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today that it has been awarded a 33-month group purchasing renewal agreement with the Premier Healthcare Alliance, a leading national healthcare group purchasing organization. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Masimo's complete market-leading line of noninvasive products and solutions, including Masimo SET® pulse oximetry, rainbow® SET Pulse CO-Oximetry,™ rainbow® Acoustic Monitoring™, and Masimo Patient SafetyNet™.
Masimo President of World Wide Sales, Marketing and clinical Research, Jon Coleman, stated, "We are happy Premier recognizes that blood transfusions represent a large cost in a hospital and has committed to providing its membership with access to Masimo rainbow® SET platform that enables clinicians to noninvasively and continuously measure total hemoglobin (SpHb®), along with many other vital parameters, to help clinicians improve blood management and advance the standard of care."
Effective June 1, 2012, through February 1, 2015, Premier members can purchase Masimo Radical-7®, Rad-87®, and portable Rad-57® and Pronto-7™ rainbow SET Pulse CO-Oximeters, and Masimo Patient SafetyNet™ on contract, along with ReSposable, Single Patient Use Adhesive, and Reusable sensors for all categories of patients (from neonatal and infant/pediatric to adult).
Masimo solutions available on contract with Premier include:
Masimo rainbow® SET Pulse CO-Oximetry
With Masimo rainbow® Pulse CO-Oximeters, clinicians can noninvasively and continuously measure many blood constituents that previously required invasive procedures, including: hemoglobin (SpHb), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRa™), in addition to Measure-Through Motion and Low Perfusion Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. And, as an upgradeable oximetry technology platform enabling new device capabilities to be added through simple field-installed software upgrades, Masimo rainbow® SET allows healthcare facilities to fight the rising costs of equipment obsolescence. Instead of costly device and hardware replacements, new noninvasive measurements and patient monitoring capabilities can be cost-effectively added to existing "rainbow-ready" Masimo oximeters via a quick, field-installed software upgrade tool.
Masimo Patient SafetyNet™ Remote Monitoring & Clinician Notification System
The Masimo SafetyNet remote monitoring and clinician notification system combines Masimo rainbow® SET Pulse CO-Oximetry and rainbow® Acoustic Monitoring with wireless clinician notifications via pager or smartphone – providing an unmatched level of safety for up to 80 patients on four floors. Masimo SafetyNet facilitates appropriate early clinical response to preempt sentinel events and avoid unnecessary ICU transfers while helping meet Joint Commission, APSF, and ASA guidelines for patient safety.
About the Premier healthcare alliance, Malcolm Baldrige National Quality Award recipient
Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 80,000-plus other healthcare sites using the power of collaboration to lead the transformation to high quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington. http://www.premierinc.com. Stay connected with Premier on Facebook, Twitter and YouTube.
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that the specificity and sensitivity of Masimo rainbow Pulse CO-Oximetry technology will provide continuous measurements of critical physiological parameters with real-time tracking and trending capabilities in all patients; risks related to the assumption that continuous Pulse CO-Oximetry measurements will enable clinicians to identify patient deterioration sooner and facilite earlier detection and treatment of potentially life-threatening conditions, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Phone: (949) 297-7434
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.